This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Source of effectiveness data
The effectiveness evidence was derived from a synthesis of published studies.
Modelling A decision tree model was constructed to simulate the costs and benefits of the three alternative combination therapies for the treatment of a hypothetical sample of 100 patients with chronic HCV infection. The time horizon of the model was one year. The model accounted for the ratio of genotype 1 to genotype 2 or genotype 3, and the positive predictive value (PPV) in response to treatment for persons with genotype 1. Treatment lasted 24 weeks for those persons nongenotype 1, while viral response was assessed at 12 weeks for genotype 1 patients. Those patients who had a decrease of 2 logs or more in viral load received an additional 36 weeks of therapy, for a total of 48 weeks. Treatment was stopped at 12 weeks for patients who did not show a viral response.
Outcomes assessed in the review
The outcomes estimated from the literature were:
the SVR for all HCV genotypes and for HCV genotype 1 only with the three combination treatments, the EVR at 12 weeks for HCV genotype 1 only with the three combination treatments, and the PPV of the three treatments for genotype 1 patients only.
Study designs and other criteria for inclusion in the review
The primary studies providing the clinical data appear to have been identified selectively rather than through a systematic review of the literature. However, the three studies selected were randomised, multi-centre, multinational, registration trials. Details of patient characteristics, dosages, follow-up, withdrawals and key efficacy results were given for each study. No direct comparison of the three combination treatments was available, thus the analysis was based on an indirect comparison (the three Peg combinations were compared with standard interferon combination therapy in three separate trials).
Sources searched to identify primary studies
Not relevant.
Criteria used to ensure the validity of primary studies
The use of international clinical trials ensures a high internal validity.
Methods used to judge relevance and validity, and for extracting data
Not reported.
Number of primary studies included
Three primary studies provided the clinical evidence.
Methods of combining primary studies
The primary studies were not combined.
Investigation of differences between primary studies
To show the baseline comparability of the patient groups, the authors reported some demographic and clinical characteristics of the three patient populations considered in the primary studies. Only the weight of the patients was slightly different.
Results of the review
The rate of SVR for all HCV genotypes was 56% with Peg-2a+RBV, 54% with Peg-2b+RBV, and 61% with the weightbased dosing regimen with Peg-2b+RBV.
The rate of SVR for HCV genotype 1 only was 46% (95% confidence interval, CI: 40 to 52) with Peg-2a+RBV, 42% (95% CI: 37 to 47) with Peg-2b+RBV, and 48% (95% CI: 39 to 57) with the weight-based dosing regimen with Peg-2b+RBV.
The rate of EVR at 12 weeks for HCV genotype 1 only was 81% (95% CI: 77 to 85) with Peg-2a+RBV, 71% (95% CI: 66 to 76) with Peg-2b+RBV, and 74% (95% CI: 66 to 82) with the weight-based dosing regimen with Peg-2b+RBV.
